# Cormorant Global Healthcare Master Fund

> Cormorant Global Healthcare Master Fund is a VC fund backing Biopharma and Health Care. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Jan 2025
- Lead investor: 25%
- Last updated: Aug 2026

Cormorant Global Healthcare Master Fund is a hedge fund specializing in public equity markets in the healthcare sector.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biopharma | 2 | 50% |
| Health Care | 2 | 50% |
| Therapeutics | 2 | 50% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 2 | 50% |
| Series A | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Interius BioTherapeutics | Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer. | $21.5M |  | Jan 01, 2025 | https://interiusbio.com |
| Tioga Cardiovascular | Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach. | $14.6M | Series A | Apr 01, 2019 | http://www.tiogamed.com/ |
| Outlook Therapeutics | Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development andtechnical excellence in order to create affordable medicines for patients around the world. |  |  | Sep 29, 2015 | https://outlooktherapeutics.com/ |
| Outlook Therapeutics | Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development andtechnical excellence in order to create affordable medicines for patients around the world. | $31M |  | Jul 27, 2015 | https://outlooktherapeutics.com/ |

4 of 4 investments shown.

## Co-investors
- Longwood Capital Partners — VC Fund, 2 deals together
- [Perceptive Advisors](https://shizune.co/investors/profile/perceptive-advisors) — VC Fund, 2 deals together
- [venBio Partners](https://shizune.co/investors/profile/venbio) — VC Fund, 2 deals together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 1 deal together
- [AMED Ventures](https://shizune.co/investors/profile/amed-ventures) — VC Fund, 1 deal together
- [Bain Capital Life Sciences](https://shizune.co/investors/profile/bain-capital-life-sciences) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Cormorant Global Healthcare Master Fund invest in?

Cormorant Global Healthcare Master Fund invests primarily in Biopharma, Health Care and Therapeutics startups, most often at Funding Round and Series A stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Cormorant Global Healthcare Master Fund last invest?

The most recent investment recorded for Cormorant Global Healthcare Master Fund closed in Jan 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co